<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04984772</url>
  </required_header>
  <id_info>
    <org_study_id>Euro-B</org_study_id>
    <secondary_id>CO-SW-985-5602</secondary_id>
    <nct_id>NCT04984772</nct_id>
  </id_info>
  <brief_title>Prospective Cohort of HIV/HBV-coinfected Patients in Europe</brief_title>
  <acronym>Euro-B</acronym>
  <official_title>Understanding Treatment Outcomes of HIV/HBV Coinfection: A Prospective Cohort of HIV/HBV-coinfected Patients in Europe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of the project is to establish an international multi-cohort research&#xD;
      platform of HIV/HBV-coinfected individuals treated with tenofovir to improve our&#xD;
      understanding of the determinants of treatment outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis B virus (HBV) infection is a major cause of morbidity and mortality among human&#xD;
      immunodeficiency virus (HIV)-infected individuals and the progression of liver disease is&#xD;
      accelerated in this population compared to HBV-monoinfected individuals. Tenofovir disoproxil&#xD;
      fumarate (TDF) or tenofovir alafenamide (TAF) as part of antiretroviral therapy (ART)&#xD;
      suppresses HBV viral load in most patients. However, risk factors of suboptimal virological&#xD;
      response to TDF/TAF and predictors of hepatitis B surface antigen (HBsAg) loss remain&#xD;
      unclear. While novel drugs for HBV therapy are being developed, a more thorough understanding&#xD;
      of the factors associated with optimal outcomes is urgent. Euro-B considers all&#xD;
      HIV/HBV-coinfected participants from EuroSIDA, the Swiss HIV cohort study and French, Spanish&#xD;
      and German HIV-HBV cohorts treated with TDF/TAF for inclusion.&#xD;
&#xD;
      The overall aim of the project is to establish an international prospective multi-cohort&#xD;
      research platform of HIV/HBV-coinfected individuals to improve our understanding of the&#xD;
      determinants of treatment outcomes, including functional cure of HBV infection. Specifically,&#xD;
      we aim to:&#xD;
&#xD;
        1. evaluate HBV virological suppression, hepatitis B e antigen (HBeAg) and HBsAg loss as&#xD;
           well as the course of quantitative HBsAg (qHBsAg) levels during TDF/TAF-containing&#xD;
           antiretroviral therapy&#xD;
&#xD;
        2. evaluate predictors of HBsAg loss and its correlation with Hepatitis B core-related&#xD;
           antigen (HBcrAg) and pre-genomic RNA (pgRNA) levels&#xD;
&#xD;
        3. explore risk factors for low-level HBV replication after 2 years of therapy&#xD;
&#xD;
        4. describe changes in liver fibrosis stage and rates of transaminase normalization over&#xD;
           time and according to HBV therapy outcome&#xD;
&#xD;
        5. assess rates and reasons of treatment interruptions or changes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 2, 2001</start_date>
  <completion_date type="Anticipated">December 31, 2030</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HBV suppression</measure>
    <time_frame>2 years of TDF/TAF-containing treatment and last available timepoint</time_frame>
    <description>Proportion of participants achieving undetectable HBV DNA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HBsAg loss</measure>
    <time_frame>2 years of TDF/TAF-containing treatment and last available timepoint</time_frame>
    <description>Proportion of participants with a negative HBsAg measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HBeAg loss</measure>
    <time_frame>2 years of TDF/TAF-containing treatment and last available timepoint</time_frame>
    <description>Proportion of participants with a negative HBeAg measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Transaminase normalization</measure>
    <time_frame>2 years of TDF/TAF-containing treatment and last available timepoint</time_frame>
    <description>Proportion of participants with transaminase normalization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver fibrosis change</measure>
    <time_frame>2 years of TDF/TAF-containing treatment and last available timepoint</time_frame>
    <description>Proportion of participants with a change in liver fibrosis stage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment interruption or change</measure>
    <time_frame>2 years of TDF/TAF-containing treatment and last available timepoint</time_frame>
    <description>Assessments of rates and reasons for treatment interruptions or changes</description>
  </primary_outcome>
  <enrollment type="Anticipated">1107</enrollment>
  <condition>HIV Infections</condition>
  <condition>Hepatitis B</condition>
  <condition>Coinfection</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma/serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV/HBV-coinfected individuals treated with tenofovir from Europe&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Study participant from contributing cohort&#xD;
&#xD;
          -  2 positive HBsAg tests more than 6 months apart&#xD;
&#xD;
          -  At least 2 data points (baseline and 2 years after TDF/TAF start either as available&#xD;
             data or stored sample&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles Wandeler, MD MSc</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Inselspital, Berne</affiliation>
  </overall_official>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 30, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Coinfection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

